What is Silence Therapeutics plc (SLN)'s fair-value range?

EvidInvest reads Silence Therapeutics plc (SLN)'s market price back into the assumptions behind it — the implied P/E, growth rate and cash yield — using its latest filed financials, then lets you set your own. See the full DCF, Graham number, EPV and multiple-based methods at https://evidinvest.com/valuation/SLN.

How is Silence Therapeutics plc (SLN)'s fair value calculated?

Silence Therapeutics plc (SLN)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples (PE, EV/EBITDA, P/S, P/B) benchmarked against its industry — using data from SEC filings.

What is Silence Therapeutics plc (SLN)'s PE ratio versus its industry?

EvidInvest shows Silence Therapeutics plc (SLN)'s current and historical PE ratio alongside its sector and industry averages, so you can see whether the stock trades at a premium or discount to peers. Full breakdown at https://evidinvest.com/valuation/SLN.

Fair value · Silence Therapeutics plc (SLN) · updated 2026-10-03 · from 20-F FY2025

Silence Therapeutics trades at $10.66. We are not reading assumptions out of that price: our price is for one ADS, which represents 3 ordinary shares, but this company files its per-share figures per ordinary share — so these methods need a per-share restatement we do not yet publish.

Everything below is unaffected: the filed statements, the filing they came from, and SLN’s growth history are all as reported.

Check another stock

The filing behind these numbers

Silence Therapeutics plc

Revenue: $559000
Diluted EPS: $-0.63
Free cash flow: $-62.3M; operating cash flow − capital expenditure
Diluted shares: 141.7M; weighted average

20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-05 · accession 0001193125-26-092591

Trailing-twelve-month EPS also uses the quarterly 6-Ks through Q2 FY2026 (filed 2026-08-10).

Open this filing on sec.gov

Valuation tool: build your own SLN range

Fair Value Summary

Daily Price — SLN

$10.64 +104.6% (1Y)

Your range0 of 7 methods

At least two methods need a usable value to draw a range with these inputs.

Range with preset inputs

No preset range for this company yet.

The two ranges are identical because every input sits on a preset.

We don’t tell you what SLN is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has SLN’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.

Discounted cash flow

N/A

Our price is for one ADS, which represents 3 ordinary shares, but this company files its per-share figures per ordinary share — so these methods need a per-share restatement we do not yet publish.

Preset inputs — revenue-driven DCF from the latest filing

Implied by today’s price

Our price is for one ADS, which represents 3 ordinary shares, but this company files its per-share figures per ordinary share — so these methods need a per-share restatement we do not yet publish.

Not solvable from the price — Our price is for one ADS, which represents 3 ordinary shares, but this company files its per-share figures per ordinary share — so these methods need a per-share restatement we do not yet publish. Showing preset inputs.

This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what SLN has actually filed, and the AI chat will reason it through with you.

Your inputs

Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.

Stage-1 growth5.0%

Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.

-20.0%60.0%

Stage-1 years5 yrs

How long stage-1 growth lasts.

1 yrs10 yrs

Stage-2 growth2.5%

Slower growth after stage 1, before the terminal phase.

-20.0%30.0%

Stage-2 years5 yrs

0 yrs10 yrs

Terminal growth2.5%

Growth forever after the two stages. Above ~3% is rarely justified.

0.0%5.0%

Discount rate (WACC)12.57%

The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.

3.00%15.00%

Net debt ($M)Debt minus cash, from the balance sheet. Subtracted from enterprise value.

Starting FCF ($M)Latest free cash flow from the filing (operating cash flow minus capex).

Shares (M)Diluted shares, from the filing.

Year by year (two-stage model, $M)

PV explicit $-419M · PV terminal $-279M · EV $-698M · equity $-687M

Year	Stage	FCF	Present value
1	Stage 1	$-65M	$-58M
2	Stage 1	$-68M	$-54M
3	Stage 1	$-72M	$-50M
4	Stage 1	$-75M	$-47M
5	Stage 1	$-79M	$-44M
6	Stage 2	$-81M	$-40M
7	Stage 2	$-83M	$-36M
8	Stage 2	$-85M	$-33M
9	Stage 2	$-87M	$-30M
10	Stage 2	$-90M	$-27M

Inputs from the filing

Free cash flow: $-42.3M; sum of the last four quarters
EBIT: $-91.1M; latest annual
Shares: 47.2M
Total debt: $160000
Cash: $11.3M
Net debt: $-11.1M; debt − cash

20-F FY2025 · period ended 2025-12-31 · filed 2026-03-05 · accession 0001193125-26-092591 · sec.gov

Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for SLN

Loading history...

Silence Therapeutics trades at $10.66. We are not reading assumptions out of that price: our price is for one ADS, which represents 3 ordinary shares, but this company files its per-share figures per ordinary share — so these methods need a per-share restatement we do not yet publish.

The filing behind these numbers

Valuation tool: build your own SLN range

Daily Price — SLN

Your range0 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on SLN

Compare with peers

Explore

Valuation tool: build your own SLN range

Daily Price — SLN

Your range0 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on SLN

Compare with peers

Explore